78 related articles for article (PubMed ID: 24107910)
1. Overexpression of CD40 in sacral chordomas and its correlation with low tumor recurrence.
Li X; Wang S; Chen Y; Liu G; Yang X
Onkologie; 2013; 36(10):567-71. PubMed ID: 24107910
[TBL] [Abstract][Full Text] [Related]
2. Analysis of risk factors for recurrence after the resection of sacral chordoma combined with embolization.
Yang H; Zhu L; Ebraheim NA; Liu X; Castillo S; Tang T; Liu J; Cui H
Spine J; 2009 Dec; 9(12):972-80. PubMed ID: 19800296
[TBL] [Abstract][Full Text] [Related]
3. Expression of vascular endothelial growth factor and matrix metalloproteinase-9 in sacral chordoma.
Chen KW; Yang HL; Lu J; Wang GL; Ji YM; Wu GZ; Zhu LF; Liu JY; Chen XQ; Gu YP
J Neurooncol; 2011 Feb; 101(3):357-63. PubMed ID: 20549300
[TBL] [Abstract][Full Text] [Related]
4. Expression of ezrin, MMP-9, and COX-2 in 50 chordoma specimens: a clinical and immunohistochemical analysis.
Froehlich EV; Scheipl S; Lazàry A; Varga PP; Schmid C; Stammberger H; Beham A; Bodo K; Schroettner H; Quehenberger F; Windhager R; Liegl B; Leithner A
Spine (Phila Pa 1976); 2012 Jun; 37(13):E757-67. PubMed ID: 22228328
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of Raf-1 and ERK1/2 in sacral chordoma and association with tumor recurrence.
Zhang K; Chen H; Zhang B; Sun J; Lu J; Chen K; Yang H
Int J Clin Exp Pathol; 2015; 8(1):608-14. PubMed ID: 25755752
[TBL] [Abstract][Full Text] [Related]
6. Expression of far upstream element-binding protein 1 correlates with c-Myc expression in sacral chordomas and is associated with tumor progression and poor prognosis.
Wen H; Ma H; Li P; Zheng J; Yu Y; Lv G
Biochem Biophys Res Commun; 2017 Sep; 491(4):1047-1054. PubMed ID: 28780352
[TBL] [Abstract][Full Text] [Related]
7. High expression of survivin in sacral chordoma.
Chen C; Yang HL; Chen KW; Wang GL; Lu J; Yuan Q; Gu YP; Luo ZP
Med Oncol; 2013 Jun; 30(2):529. PubMed ID: 23504337
[TBL] [Abstract][Full Text] [Related]
8. A review of the surgical management of sacral chordoma.
Kayani B; Hanna SA; Sewell MD; Saifuddin A; Molloy S; Briggs TW
Eur J Surg Oncol; 2014 Nov; 40(11):1412-20. PubMed ID: 24793103
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of MIB-1, E-cadherin, and CD44 in pediatric chordomas.
Saad AG; Collins MH
Pediatr Dev Pathol; 2005; 8(3):362-8. PubMed ID: 16010499
[TBL] [Abstract][Full Text] [Related]
10. Does insulin-like growth factor 1 receptor (IGF-1R) targeting provide new treatment options for chordomas? A retrospective clinical and immunohistochemical study.
Scheipl S; Froehlich EV; Leithner A; Beham A; Quehenberger F; Mokry M; Stammberger H; Varga PP; Lazáry A; Windhager R; Gattenloehner S; Liegl B
Histopathology; 2012 May; 60(6):999-1003. PubMed ID: 22372631
[TBL] [Abstract][Full Text] [Related]
11. [Sacral chordoma: retrospective review of 11 surgically treated cases].
Jeanrot C; Vinh TS; Anract P; De Pinieux G; Ouaknine M; Forest M; Tomeno B
Rev Chir Orthop Reparatrice Appar Mot; 2000 Nov; 86(7):684-93. PubMed ID: 11104990
[TBL] [Abstract][Full Text] [Related]
12. Sacral chordomas: Impact of high-dose proton/photon-beam radiation therapy combined with or without surgery for primary versus recurrent tumor.
Park L; Delaney TF; Liebsch NJ; Hornicek FJ; Goldberg S; Mankin H; Rosenberg AE; Rosenthal DI; Suit HD
Int J Radiat Oncol Biol Phys; 2006 Aug; 65(5):1514-21. PubMed ID: 16757128
[TBL] [Abstract][Full Text] [Related]
13. High expression of SPHK1 in sacral chordoma and association with patients' poor prognosis.
Zhang K; Chen H; Wu G; Chen K; Yang H
Med Oncol; 2014 Nov; 31(11):247. PubMed ID: 25260803
[TBL] [Abstract][Full Text] [Related]
14. Chordomas: a histological and immunohistochemical study of cases with and without recurrent tumors.
Sell M; Sampaolo S; Di Lorio G; Theallier A
Clin Neuropathol; 2004; 23(6):277-85. PubMed ID: 15584212
[TBL] [Abstract][Full Text] [Related]
15. Definitive high-dose photon/proton radiotherapy for unresected mobile spine and sacral chordomas.
Chen YL; Liebsch N; Kobayashi W; Goldberg S; Kirsch D; Calkins G; Childs S; Schwab J; Hornicek F; DeLaney T
Spine (Phila Pa 1976); 2013 Jul; 38(15):E930-6. PubMed ID: 23609202
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of immunohistochemical expression of VEGFR2 and iNOS in spinal chordoma.
Akhavan-Sigari R; Gaab MR; Rohde V; Abili M; Ostertag H
Eur Spine J; 2014 Nov; 23(11):2416-22. PubMed ID: 24929808
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of cetuximab/gefitinib in the therapy of a sacral chordoma.
Hof H; Welzel T; Debus J
Onkologie; 2006 Dec; 29(12):572-4. PubMed ID: 17202828
[TBL] [Abstract][Full Text] [Related]
18. Effect of carbon ion radiotherapy for sacral chordoma: results of Phase I-II and Phase II clinical trials.
Imai R; Kamada T; Tsuji H; Sugawara S; Serizawa I; Tsujii H; Tatezaki S;
Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1470-6. PubMed ID: 19939576
[TBL] [Abstract][Full Text] [Related]
19. Examination of survivin expression in 50 chordoma specimens--A histological and in vitro study.
Froehlich EV; Rinner B; Deutsch AJ; Meditz K; Knausz H; Troppan K; Scheipl S; Wibmer C; Leithner A; Liegl B; Lohberger B
J Orthop Res; 2015 May; 33(5):771-8. PubMed ID: 25640185
[TBL] [Abstract][Full Text] [Related]
20. Analysis of immunohistochemical expression of p53 and the proliferation marker Ki-67 antigen in skull base chordomas: relationships between their expression and prognosis.
Sakai K; Hongo K; Tanaka Y; Nakayama J
Brain Tumor Pathol; 2007; 24(2):57-62. PubMed ID: 18095132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
